S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:AERI

Aerie Pharmaceuticals Competitors

$19.25
-0.31 (-1.58 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.71
Now: $19.25
$19.96
50-Day Range
$13.95
MA: $16.73
$19.80
52-Week Range
$9.01
Now: $19.25
$20.46
Volume1.25 million shs
Average Volume809,608 shs
Market Capitalization$903.15 million
P/E RatioN/A
Dividend YieldN/A
Beta0.79

Competitors

Aerie Pharmaceuticals (NASDAQ:AERI) Vs. RLAY, SWTX, RVMD, NK, EDIT, and NSTG

Should you be buying AERI stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Aerie Pharmaceuticals, including Relay Therapeutics (RLAY), SpringWorks Therapeutics (SWTX), Revolution Medicines (RVMD), NantKwest (NK), Editas Medicine (EDIT), and NanoString Technologies (NSTG).

Relay Therapeutics (NASDAQ:RLAY) and Aerie Pharmaceuticals (NASDAQ:AERI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Relay Therapeutics and Aerie Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relay Therapeutics01502.83
Aerie Pharmaceuticals11902.73

Relay Therapeutics presently has a consensus target price of $57.40, suggesting a potential upside of 43.54%. Aerie Pharmaceuticals has a consensus target price of $25.50, suggesting a potential upside of 32.47%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Relay Therapeutics is more favorable than Aerie Pharmaceuticals.

Profitability

This table compares Relay Therapeutics and Aerie Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relay TherapeuticsN/AN/AN/A
Aerie Pharmaceuticals-231.05%-135.57%-37.23%

Institutional and Insider Ownership

98.4% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 99.9% of Aerie Pharmaceuticals shares are owned by institutional investors. 9.7% of Aerie Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Relay Therapeutics and Aerie Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay TherapeuticsN/AN/AN/AN/AN/A
Aerie Pharmaceuticals$69.89 million12.92$-199,580,000.00($3.40)-5.66

Relay Therapeutics has higher earnings, but lower revenue than Aerie Pharmaceuticals.

Summary

Relay Therapeutics beats Aerie Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and Aerie Pharmaceuticals (NASDAQ:AERI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Risk and Volatility

SpringWorks Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Aerie Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for SpringWorks Therapeutics and Aerie Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpringWorks Therapeutics00303.00
Aerie Pharmaceuticals11902.73

SpringWorks Therapeutics presently has a consensus target price of $91.00, suggesting a potential upside of 31.31%. Aerie Pharmaceuticals has a consensus target price of $25.50, suggesting a potential upside of 32.47%. Given Aerie Pharmaceuticals' higher possible upside, analysts clearly believe Aerie Pharmaceuticals is more favorable than SpringWorks Therapeutics.

Profitability

This table compares SpringWorks Therapeutics and Aerie Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpringWorks TherapeuticsN/A-24.48%-23.58%
Aerie Pharmaceuticals-231.05%-135.57%-37.23%

Institutional and Insider Ownership

76.3% of SpringWorks Therapeutics shares are owned by institutional investors. Comparatively, 99.9% of Aerie Pharmaceuticals shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by insiders. Comparatively, 9.7% of Aerie Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares SpringWorks Therapeutics and Aerie Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-19.52
Aerie Pharmaceuticals$69.89 million12.92$-199,580,000.00($3.40)-5.66

SpringWorks Therapeutics has higher earnings, but lower revenue than Aerie Pharmaceuticals. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Aerie Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

SpringWorks Therapeutics beats Aerie Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Aerie Pharmaceuticals (NASDAQ:AERI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

85.8% of Revolution Medicines shares are owned by institutional investors. Comparatively, 99.9% of Aerie Pharmaceuticals shares are owned by institutional investors. 9.7% of Aerie Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Revolution Medicines and Aerie Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines01402.80
Aerie Pharmaceuticals11902.73

Revolution Medicines presently has a consensus target price of $50.75, suggesting a potential upside of 19.55%. Aerie Pharmaceuticals has a consensus target price of $25.50, suggesting a potential upside of 32.47%. Given Aerie Pharmaceuticals' higher possible upside, analysts clearly believe Aerie Pharmaceuticals is more favorable than Revolution Medicines.

Earnings and Valuation

This table compares Revolution Medicines and Aerie Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million56.31$-47,660,000.00N/AN/A
Aerie Pharmaceuticals$69.89 million12.92$-199,580,000.00($3.40)-5.66

Revolution Medicines has higher earnings, but lower revenue than Aerie Pharmaceuticals.

Profitability

This table compares Revolution Medicines and Aerie Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
Aerie Pharmaceuticals-231.05%-135.57%-37.23%

Summary

Revolution Medicines beats Aerie Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Aerie Pharmaceuticals (NASDAQ:AERI) and NantKwest (NASDAQ:NK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

99.9% of Aerie Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of NantKwest shares are owned by institutional investors. 9.7% of Aerie Pharmaceuticals shares are owned by company insiders. Comparatively, 71.7% of NantKwest shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aerie Pharmaceuticals and NantKwest, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aerie Pharmaceuticals11902.73
NantKwest00103.00

Aerie Pharmaceuticals presently has a consensus price target of $25.50, suggesting a potential upside of 32.47%. NantKwest has a consensus price target of $18.00, suggesting a potential downside of 30.10%. Given Aerie Pharmaceuticals' higher probable upside, analysts plainly believe Aerie Pharmaceuticals is more favorable than NantKwest.

Earnings & Valuation

This table compares Aerie Pharmaceuticals and NantKwest's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerie Pharmaceuticals$69.89 million12.92$-199,580,000.00($3.40)-5.66
NantKwest$40,000.0070,166.82$-65,790,000.00($0.70)-36.79

NantKwest has lower revenue, but higher earnings than Aerie Pharmaceuticals. NantKwest is trading at a lower price-to-earnings ratio than Aerie Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Aerie Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500.

Profitability

This table compares Aerie Pharmaceuticals and NantKwest's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aerie Pharmaceuticals-231.05%-135.57%-37.23%
NantKwest-76,658.58%-56.06%-46.93%

Aerie Pharmaceuticals (NASDAQ:AERI) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

99.9% of Aerie Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.5% of Editas Medicine shares are owned by institutional investors. 9.7% of Aerie Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aerie Pharmaceuticals and Editas Medicine, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aerie Pharmaceuticals11902.73
Editas Medicine34302.00

Aerie Pharmaceuticals presently has a consensus price target of $25.50, suggesting a potential upside of 32.47%. Editas Medicine has a consensus price target of $49.2222, suggesting a potential upside of 21.96%. Given Aerie Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Aerie Pharmaceuticals is more favorable than Editas Medicine.

Earnings & Valuation

This table compares Aerie Pharmaceuticals and Editas Medicine's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerie Pharmaceuticals$69.89 million12.92$-199,580,000.00($3.40)-5.66
Editas Medicine$20.53 million132.43$-133,750,000.00($2.68)-15.06

Editas Medicine has lower revenue, but higher earnings than Aerie Pharmaceuticals. Editas Medicine is trading at a lower price-to-earnings ratio than Aerie Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Aerie Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.

Profitability

This table compares Aerie Pharmaceuticals and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aerie Pharmaceuticals-231.05%-135.57%-37.23%
Editas Medicine-99.62%-26.74%-16.38%

Aerie Pharmaceuticals (NASDAQ:AERI) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

99.9% of Aerie Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 9.7% of Aerie Pharmaceuticals shares are owned by company insiders. Comparatively, 4.2% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aerie Pharmaceuticals and NanoString Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aerie Pharmaceuticals11902.73
NanoString Technologies01502.83

Aerie Pharmaceuticals presently has a consensus price target of $25.50, suggesting a potential upside of 32.47%. NanoString Technologies has a consensus price target of $63.00, suggesting a potential upside of 3.26%. Given Aerie Pharmaceuticals' higher probable upside, analysts plainly believe Aerie Pharmaceuticals is more favorable than NanoString Technologies.

Earnings & Valuation

This table compares Aerie Pharmaceuticals and NanoString Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerie Pharmaceuticals$69.89 million12.92$-199,580,000.00($3.40)-5.66
NanoString Technologies$125.57 million21.41$-40,700,000.00($1.93)-31.61

NanoString Technologies has higher revenue and earnings than Aerie Pharmaceuticals. NanoString Technologies is trading at a lower price-to-earnings ratio than Aerie Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Aerie Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Profitability

This table compares Aerie Pharmaceuticals and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aerie Pharmaceuticals-231.05%-135.57%-37.23%
NanoString Technologies-53.47%-68.96%-24.15%

Summary

NanoString Technologies beats Aerie Pharmaceuticals on 9 of the 14 factors compared between the two stocks.


Aerie Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
RLAY
Relay Therapeutics
1.8$39.99-3.5%$3.60 billionN/A0.00
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$69.30-7.8%$3.39 billionN/A-39.83Analyst Report
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$42.45-1.7%$2.82 billion$50.04 million0.00Earnings Announcement
Analyst Report
NantKwest logo
NK
NantKwest
1.1$25.75-3.2%$2.81 billion$40,000.00-36.27Decrease in Short Interest
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.36-6.9%$2.72 billion$20.53 million-23.20Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$61.01-12.9%$2.69 billion$125.57 million-35.68Earnings Announcement
Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81-3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53-7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.